
Guglielmo Ronco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8624900/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet, The, 2014, 383, 524-532.	13.7	1,282
2	Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncology, The, 2010, 11, 249-257.	10.7	797
3	Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer. Vaccine, 2012, 30, F88-F99.	3.8	695
4	Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. International Journal of Cancer, 2009, 124, 516-520.	5.1	557
5	Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries. Vaccine, 2008, 26, K29-K41.	3.8	526
6	Variations in the ageâ€specific curves of human papillomavirus prevalence in women worldwide. International Journal of Cancer, 2006, 119, 2677-2684.	5.1	332
7	Human Papillomavirus Testing and Liquid-Based Cytology: Results at Recruitment From the New Technologies for Cervical Cancer Randomized Controlled Trial. Journal of the National Cancer Institute, 2006, 98, 765-774.	6.3	275
8	Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test. Journal of the National Cancer Institute, 2008, 100, 492-501.	6.3	259
9	Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ: British Medical Journal, 2007, 335, 28.	2.3	224
10	EUROGIN 2011 roadmap on prevention and treatment of HPVâ€related disease. International Journal of Cancer, 2012, 131, 1969-1982.	5.1	204
11	Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncology, The, 2006, 7, 547-555.	10.7	202
12	European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 22-31.	4.5	181
13	Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncology, The, 2008, 9, 937-945.	10.7	170
14	Status of implementation and organization of cancer screening in The European Union Member States—Summary results from the second European screening report. International Journal of Cancer, 2018, 142, 44-56.	5.1	169
15	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology, 2016, 13, 119-132.	27.6	154
16	Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncology, The, 2013, 14, 168-176.	10.7	139
17	MicroRNAs as markers of progression in cervical cancer: a systematic review. BMC Cancer, 2018, 18, 696.	2.6	135
18	Cervical cancer screening policies and coverage in Europe. European Journal of Cancer, 2009, 45, 2649-2658.	2.8	132

#	Article	IF	CITATIONS
19	Eurogin roadmap 2017: Triage strategies for the management of <scp>HPV</scp> â€positive women in cervical screening programs. International Journal of Cancer, 2018, 143, 735-745.	5.1	124
20	Reproductive Factors, Oral Contraceptive Use, and Human Papillomavirus Infection: Pooled Analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2148-2153.	2.5	118
21	Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report. Gut, 2019, 68, 1232-1244.	12.1	113
22	Description of the national situation of cervical cancer screening in the member states of the European Union. European Journal of Cancer, 2009, 45, 2685-2708.	2.8	98
23	Chapter 10: New dimensions in cervical cancer screening. Vaccine, 2006, 24, S90-S97.	3.8	95
24	Prevalence of human papillomavirus infection in women in Turin, Italy. European Journal of Cancer, 2005, 41, 297-305.	2.8	94
25	How to evaluate emerging technologies in cervical cancer screening?. International Journal of Cancer, 2009, 125, 2489-2496.	5.1	91
26	Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. American Journal of Clinical Pathology, 2005, 124, 716-721.	0.7	90
27	The clinical impact of using p16 INK4a immunochemistry in cervical histopathology and cytology: An update of recent developments. International Journal of Cancer, 2015, 136, 2741-2751.	5.1	84
28	The Reproducibility of CIN Diagnoses Among Different Pathologists. American Journal of Clinical Pathology, 2009, 132, 125-132.	0.7	82
29	Eurogin 2010 roadmap on cervical cancer prevention. International Journal of Cancer, 2011, 128, 2765-2774.	5.1	75
30	Occult HCV Infection: An Unexpected Finding in a Population Unselected for Hepatic Disease. PLoS ONE, 2009, 4, e8128.	2.5	66
31	HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. European Journal of Cancer, 2007, 43, 476-480.	2.8	65
32	Occupation and lung cancer in two industrialized areas of northern Italy. International Journal of Cancer, 1988, 41, 354-358.	5.1	63
33	Informed Cytology for Triaging HPV-Positive Women: Substudy Nested in the NTCC Randomized Controlled Trial. Journal of the National Cancer Institute, 2015, 107, .	6.3	61
34	A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. International Journal of Cancer, 2006, 118, 791-796.	5.1	60
35	Small non-coding RNA profiling in human biofluids and surrogate tissues from healthy individuals: description of the diverse and most represented species. Oncotarget, 2018, 9, 3097-3111.	1.8	56
36	Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. American Journal of Clinical Pathology, 2005, 124, 716-721.	0.7	54

#	Article	lF	CITATIONS
37	Process performance of cervical screening programmes in Europe. European Journal of Cancer, 2009, 45, 2659-2670.	2.8	53
38	Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. European Journal of Cancer, 2012, 48, 1633-1637.	2.8	50
39	Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference. Preventive Medicine, 2017, 98, 21-30.	3.4	49
40	What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. European Journal of Cancer, 2009, 45, 2714-2721.	2.8	44
41	HPV prevalence and accuracy of HPV testing to detect highâ€grade cervical intraepithelial neoplasia. International Journal of Cancer, 2012, 130, 1387-1394.	5.1	44
42	p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women. Journal of the National Cancer Institute, 2021, 113, 292-300.	6.3	41
43	Who Has Pap Tests?: Variables Associated with the Use of Pap Tests in Absence of Screening Programmes. International Journal of Epidemiology, 1991, 20, 349-353.	1.9	40
44	The Risk of False-Positive Histology According to the Reason for Colposcopy Referral in Cervical Cancer Screening. American Journal of Clinical Pathology, 2008, 129, 75-80.	0.7	40
45	Accuracy of the umbilical arteries Doppler flow velocity waveforms in detecting adverse perinatal outcomes in a high-risk population. Acta Obstetricia Et Gynecologica Scandinavica, 1996, 75, 113-119.	2.8	38
46	Screening patterns within organized programs and survival of Italian women with invasive cervical cancer. Preventive Medicine, 2013, 57, 220-226.	3.4	37
47	The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening Programs. Frontiers in Oncology, 2014, 4, 20.	2.8	37
48	Impact of variations in triage cytology interpretation onÂhuman papillomavirus–based cervical screening andÂimplications for screening algorithms. European Journal of Cancer, 2016, 68, 148-155.	2.8	37
49	Interpretation of p16 ^{INK4a} /Kiâ€67 dual immunostaining for the triage of human papillomavirusâ€positive women by experts and nonexperts in cervical cytology. Cancer Cytopathology, 2015, 123, 212-218.	2.4	35
50	Changes in cervical cancer incidence following the introduction of organized screening in Italy. Preventive Medicine, 2015, 75, 56-63.	3.4	35
51	Impact of the introduction of organised screening for cervical cancer in Turin, Italy: cancer incidence by screening history 1992–98. British Journal of Cancer, 2005, 93, 376-378.	6.4	34
52	Detection of human papillomavirus type 16 integration in pre-neoplastic cervical lesions and confirmation by DIPS-PCR and sequencing. Journal of Clinical Virology, 2007, 38, 7-13.	3.1	33
53	The value of the 1981 who histological classification in inter-observer reproducibility and changing pattern of lung cancer. International Journal of Cancer, 1993, 53, 205-208.	5.1	31
54	HPV testing for primary cervical cancer screening. Lancet, The, 2007, 370, 1740-1742.	13.7	28

#	Article	IF	CITATIONS
55	HPV-16 infection and cervical cancer: Modeling the influence of duration of infection and precancerous lesions. Epidemics, 2010, 2, 21-28.	3.0	27
56	Clinical Impact of the Analytical Specificity of the Hybrid Capture 2 Test: Data from the New Technologies for Cervical Cancer (NTCC) Study. Journal of Clinical Microbiology, 2013, 51, 2901-2907.	3.9	26
57	Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence. Journal of Clinical Virology, 2014, 60, 257-263.	3.1	25
58	Interobserver reproducibility of cytologic p16 ^{INK4a} /Kiâ€67 dual immunostaining in human papillomavirusâ€positive women. Cancer Cytopathology, 2017, 125, 212-220.	2.4	25
59	New paradigms in cervical cancer prevention: opportunities and risks. BMC Women's Health, 2008, 8, 23.	2.0	24
60	Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. Vaccine, 2011, 29, 1270-1277.	3.8	24
61	Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates. PLoS ONE, 2013, 8, e81171.	2.5	21
62	A first survey of HPV-based screening in routine cervical cancer screening in Italy. Epidemiologia E Prevenzione, 2015, 39, 77-83.	1.1	21
63	Performance of <scp>HPV E6</scp> / <scp>E7 mRNA</scp> assay as primary screening test: Results from the <scp>NTCC2</scp> trial. International Journal of Cancer, 2022, 151, 1047-1058.	5.1	21
64	GP5+/6+ SYBR Green methodology for simultaneous screening and quantification of human papillomavirus. Journal of Clinical Virology, 2009, 45, 90-95.	3.1	20
65	A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18–26Âyears. BMC Infectious Diseases, 2013, 13, 74.	2.9	20
66	Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study. Journal of Infectious Diseases, 2017, 216, 336-344.	4.0	20
67	Human papillomavirus typing with GP5+/6+ polymerase chain reaction reverse line blotting and with commercial type-specific PCR kits. Journal of Clinical Virology, 2006, 36, 126-132.	3.1	19
68	Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial. BMC Infectious Diseases, 2013, 13, 238.	2.9	19
69	Role of HPV DNA testing in modern gynaecological practice. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2018, 47, 107-118.	2.8	19
70	<scp>I</scp> mpacts of human papillomavirus vaccination for different populations: <scp>A</scp> modeling study. International Journal of Cancer, 2018, 143, 1086-1092.	5.1	18
71	The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. Gynecologic Oncology, 2007, 107, S230-S232.	1.4	17
72	Accuracy of liquidâ€based cytology. Cancer Cytopathology, 2010, 118, 203-208.	2.4	16

#	Article	IF	CITATIONS
73	Human papilloma virus genotyping for the crossâ€sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more. International Journal of Cancer, 2018, 143, 333-342.	5.1	16
74	Invitation strategies and coverage in the population-based cancer screening programmes in the European Union. European Journal of Cancer Prevention, 2019, 28, 131-140.	1.3	16
75	Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for highâ€risk human papillomavirus at primary screening. International Journal of Cancer, 2020, 147, 1864-1873.	5.1	16
76	Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries. International Journal of Cancer, 2013, 133, 1876-1881.	5.1	14
77	Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infectious Agents and Cancer, 2014, 9, 4.	2.6	14
78	Impact of the AutoPap (currently focalpoint) primary screening system location guide use on interpretation time and diagnosis. Cancer, 2002, 99, 83-88.	4.1	12
79	The Present and Future of Cervical Cancer Screening Programmes in Europe. Current Pharmaceutical Design, 2013, 19, 1490-1497.	1.9	12
80	The present and future of cervical cancer screening programmes in Europe. Current Pharmaceutical Design, 2013, 19, 1490-7.	1.9	12
81	A First Survey of Organized Cervical Cancer Screening Programs in Italy. Tumori, 1998, 84, 624-630.	1.1	11
82	Cervical cancer screening in Europe – Changes over the last 9 years. European Journal of Cancer, 2009, 45, 2629-2631.	2.8	11
83	HPV Testing Is an Efficient Management Choice for Women With Inadequate Liquid-Based Cytology in Cervical Cancer Screening. American Journal of Clinical Pathology, 2012, 138, 65-71.	0.7	11
84	The Age Distribution of Type-Specific High-Risk Human Papillomavirus Incidence in Two Population-Based Screening Trials. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 111-118.	2.5	11
85	Consent for Research With Biological Samples: One-Time General Consent Versus a Gift Model. Annals of Internal Medicine, 2012, 156, 596.	3.9	11
86	The impact of new technologies in cervical cancer screening: Results of the recruitment phase of a large randomised controlled trial from a public health perspective. International Journal of Cancer, 2007, 121, 2729-2734.	5.1	10
87	HPV-based screening for prevention of invasive cervical cancer – Authors' reply. Lancet, The, 2014, 383, 1295.	13.7	10
88	Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion. Cancer Cytopathology, 2016, 124, 66-67.	2.4	10
89	Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types. Journal of Clinical Microbiology, 2017, 55, 1056-1065.	3.9	10
90	Extension of organized cervical cancer screening programmes in Italy and their process indicators, 2011-2012 activity. Epidemiologia E Prevenzione, 2015, 39, 61-76.	1.1	10

#	Article	IF	CITATIONS
91	Effect of circulation and discussion of cervical smears on agreement between laboratories. Cytopathology, 2003, 14, 115-120.	0.7	9
92	Inequalities in cervical cancer screening utilisation and results: A comparison between Italian natives and immigrants from disadvantaged countries. Health Policy, 2017, 121, 1072-1078.	3.0	9
93	Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions: evidence from an international multi-centre study. Breast Cancer Research and Treatment, 2019, 177, 761-765.	2.5	9
94	The length of pregnancy: An echographic reappraisal. Journal of Clinical Ultrasound, 1991, 19, 11-14.	0.8	8
95	The prevention of cervical cancer in HIV-infected women. Aids, 2010, 24, 2579-2580.	2.2	8
96	HPV16 and HPV18 genotyping in cervical cancer screening. Lancet Oncology, The, 2011, 12, 831-832.	10.7	7
97	Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screenâ€detected cervical precancer. International Journal of Cancer, 2021, 148, 320-328.	5.1	7
98	Assessment of viral methylation levels for high risk HPV types by newly designed consensus primers PCR and pyrosequencing. PLoS ONE, 2018, 13, e0194619.	2.5	7
99	Performance indicators in breast cancer screening in the European Union: A comparison across countries of screen positivity and detection rates. International Journal of Cancer, 2020, 147, 1855-1863.	5.1	6
100	Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening. International Journal of Cancer, 2020, 147, 9-13.	5.1	6
101	Determinants of p16/Kiâ€67 adequacy and positivity in HPVâ€positive women from a screening population. Cancer Cytopathology, 2021, 129, 383-393.	2.4	6
102	The differential diagnosis of primary lung cancer: Inter-observer agreement and contribution of specific diagnostic procedures. Journal of Clinical Epidemiology, 1992, 45, 827-833.	5.0	5
103	Cervical Cancer Screening: The Transformational Role of Routine Human Papillomavirus Testing. Annals of Internal Medicine, 2018, 168, 75.	3.9	5
104	Extension of organised cervical cancer screening programmes in Italy and their process indicators. Epidemiologia E Prevenzione, 2008, 32, 37-54.	1.1	5
105	Assessment of specimen adequacy reproducibility: An Italian experience. Diagnostic Cytopathology, 2003, 28, 224-226.	1.0	4
106	HPV Screening: Available Data and Recommendations for Clinical Practice. Current Cancer Therapy Reviews, 2010, 6, 104-109.	0.3	4
107	HPV test shows low sensitivity of Pap screen in older women – Authors' reply. Lancet Oncology, The, 2010, 11, 510-511.	10.7	2
108	HPV types in early-onset cervical cancer. Lancet Oncology, The, 2011, 12, 117.	10.7	2

#	Article	IF	CITATIONS
109	Extension of organised cervical cancer screening programmes in Italy and their process indicators, 2009 activity. Epidemiologia E Prevenzione, 2011, 35, 39-54.	1.1	2
110	Efficacy of HPV-Based Screening for Prevention of Invasive Cervical Cancer. Obstetrical and Gynecological Survey, 2014, 69, 472-473.	0.4	1
111	Causal system modelling of cervical cancer screening. Lancet Public Health, The, 2017, 2, e61-e62.	10.0	1
112	Cervical cancer screening in Italy: quality of colposcopy and treatment. 2009 activity. Epidemiologia E Prevenzione, 2011, 35, 78-86.	1.1	1
113	Author's reply to: Implementation and organization of cancer screening in France. International Journal of Cancer, 2018, 143, 3035-3035.	5.1	0
114	Author's reply to: Cancer screening policy in <scp>H</scp> ungary. International Journal of Cancer, 2018, 143, 1005-1005.	5.1	0
115	Response to the author: invitation to cancer screening: putting the car before the horse?. European Journal of Cancer Prevention, 2019, 28, 458-459.	1.3	0
116	Infections and cancer: the contribution of European research in recent progresses. Epidemiologia E Prevenzione, 2010, 34, 56-61.	1.1	0